dc.contributor.author | Bracarda, S | |
dc.contributor.author | Negrier, S | |
dc.contributor.author | Casper, J | |
dc.contributor.author | Porta, C | |
dc.contributor.author | Schmidinger, M | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Gross Goupil, M | |
dc.contributor.author | Escudier, B | |
dc.date.accessioned | 2017-04-13T09:40:21Z | |
dc.date.issued | 2017-03 | |
dc.identifier.citation | Expert review of anticancer therapy, 2017, 17 (3), pp. 227 - 233 | |
dc.identifier.issn | 1473-7140 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/587 | |
dc.identifier.eissn | 1744-8328 | |
dc.identifier.doi | 10.1080/14737140.2017.1276830 | |
dc.description.abstract | Introduction Currently, sunitinib is a standard of care in first-line treatment for metastatic renal cell carcinoma (mRCC). However, with the standard 4/2 schedule (sunitinib 50 mg/day; 4 consecutive weeks on treatment; 2 weeks' rest), 50% of patients require dose reductions to mitigate toxicity, highlighting the need to investigate alternative dosing schedules that improve tolerability without compromising efficacy. Areas covered: We present a concise critical review of published studies comparing the efficacy and safety of the 4/2 and 2/1 schedule (2 weeks on treatment; 1 week rest) for sunitinib. While all studies evaluating the 2/1 schedule have a low level of evidence, the results indicate that the 2/1 schedule improves tolerability compared with the 4/2 schedule, including significant reductions in the incidence of specific adverse events. It was not possible to make any definitive conclusions regarding efficacy due to methodologic limitations of these studies. Expert commentary: In the absence of strong evidence supporting the safety and efficacy of the 2/1 schedule, we recommend that patients should be initiated on sunitinib therapy with the standard 4/2 schedule and only be switched to the 2/1 schedule after the development of dose-limiting toxicities from weeks 3-4 (cycle 1) of the 4/2 schedule cycle. | |
dc.format | Print-Electronic | |
dc.format.extent | 227 - 233 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Carcinoma, Renal Cell | |
dc.subject | Kidney Neoplasms | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Pyrroles | |
dc.subject | Indoles | |
dc.subject | Antineoplastic Agents | |
dc.subject | Drug Administration Schedule | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Research Design | |
dc.subject | Sunitinib | |
dc.title | How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1080/14737140.2017.1276830 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-03 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Expert review of anticancer therapy | |
pubs.issue | 3 | |
pubs.notes | 12 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 17 | |
pubs.embargo.terms | 12 months | |
icr.researchteam | Melanoma and Kidney Cancer | en_US |
dc.contributor.icrauthor | Larkin, James | |
dc.contributor.icrauthor | Marsden, | |